Search

Your search keyword '"Luciana K. Tanno"' showing total 14 results
Start Over Author "Luciana K. Tanno"
14 results on '"Luciana K. Tanno"'

1. Updated grading system for systemic allergic reactions: Joint Statement of the World Allergy Organization Anaphylaxis Committee and Allergen Immunotherapy Committee

Author

Paul J. Turner, MD, PhD, Ignacio J. Ansotegui, MD, PhD, Dianne E. Campbell, MD, PhD, Victoria Cardona, MD, PhD, Stuart Carr, MD, Adnan Custovic, MD, PhD, Stephen Durham, MD, Motohiro Ebisawa, MD, PhD, Mario Geller, MD, Alexei Gonzalez-Estrada, MD, Paul A. Greenberger, MD, Elham Hossny, MD, PhD, Carla Irani, MD, Agnes S.Y. Leung, MD, Michael E. Levin, MD, PhD, Antonella Muraro, MD, John J. Oppenheimer, MD, José Antonio Ortega Martell, MD, Guillaume Pouessel, MD, Manuel J. Rial, MD, PhD, Gianenrico Senna, MD, PhD, Luciana K. Tanno, MD, PhD, Dana V. Wallace, MD, Margitta Worm, MD, PhD, and Mário Morais-Almeida, MD, PhD

Subjects
Adverse events, Allergen immunotherapy, Anaphylaxis, Clinical trials, Safety reporting, Immunologic diseases. Allergy, RC581-607
Abstract

There is a lack of consensus over the description and severity assignment of allergic adverse reactions to immunotherapy, although there seems to be a consensus at least in terms of using the World Allergy Organization (WAO) grading systems to describe local adverse events for Sublingual Immunotherapy (SLIT) and Systemic Allergic Reactions (SARs) to Subcutaneous Immunotherapy (SCIT) amongst the major national/regional allergy societies. In this manuscript, we propose a modification of the previous WAO Grading system for SARs, which aligns with the newly-proposed Consortium for Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions in Food Allergy (version 3.0). We hope this can facilitate a unified grading system appropriate to SARs due to allergen immunotherapy, independent of allergen and route of administration, and across clinical and research practice.

Published
2024
Full Text
View/download PDF

2. WAO consensus on DEfinition of Food Allergy SEverity (DEFASE)

Author

Stefania Arasi, MD, PhD, MSc, Ulugbek Nurmatov, MD, Audrey Dunn-Galvin, PhD, Graham Roberts, DM, Paul J. Turner, FRCPCH, PhD, Sayantani B. Shinder, MD, PhD, Ruchi Gupta, MD, MPh, Philippe Eigenmann, MD, Anna Nowak-Wegrzyn, MD, PhD, Ignacio J. Ansotegui, MD, PhD, Montserrat Fernandez Rivas, MD, Stavros Petrou, PhD, Luciana K. Tanno, MD, PhD, Marta Vazquez-Ortiz, MD, PhD, Brian Vickery, MD, PhD, Gary Wong, MD, FRCPC, Montserrat Alvaro-Lozano, MD, PhD, Miqdad Asaria, PhD, Philippe Begin, MD, MSc, Martin Bozzola, MD, Robert Boyle, MD, Helen Brough, MD, PhD, Victoria Cardona, MD, PhD, R. Sharon Chinthrajah, MD, PhD, Antonella Cianferoni, MD, Antoine Deschildre, MD, David Fleischer, MD, Flavio Gazzani, PhD, Jennifer Gerdts, Marilena Giannetti, PhD, Matthew Greenhawt, MD, MBA, MSc, Maria Antonieta Guzmán, MD, Elham Hossny, MD, PhD, FAAAAI, Paula Kauppi, MD, Carla Jones, Francesco Lucidi, PhD, Olga Patricia Monge Ortega, MD, PhD, Daniel Munblit, MD, PhD, Antonella Muraro, MD, Giovanni Pajno, MD, Marcia Podestà, Pablo Rodriguez del Rio, MD, PhD, Maria Said, Alexandra Santos, MD, MSc, MRCPCH, PGCAP, FHEA, PhD, Marcus Shaker, MD, Hania Szajewska, MD, PhD, Carina Venter, PhD, Cristopher Warren, PhD, Tonya Winders, Motohiro Ebisawa, MD, PhD, and Alessandro Fiocchi, MD

Subjects
Consensus, Definition, Food allergy, Severity, e-Delphi study, Immunologic diseases. Allergy, RC581-607
Abstract

Background: While several scoring systems for the severity of anaphylactic reactions have been developed, there is a lack of consensus on definition and categorisation of severity of food allergy disease as a whole. Aim: To develop an international consensus on the severity of food allergy (DEfinition of Food Allergy Severity, DEFASE) scoring system, to be used globally. Methods: Phase 1: We conducted a mixed-method systematic review (SR) of 11 databases for published and unpublished literature on severity of food allergy management and set up a panel of international experts. Phase 2: Based on our findings in Phase 1, we drafted statements for a two-round modified electronic Delphi (e-Delphi) survey. A purposefully selected multidisciplinary international expert panel on food allergy (n = 60) was identified and sent a structured questionnaire, including a set of statements on different domains of food allergy severity related to symptoms, health-related quality of life, and economic impact. Participants were asked to score their agreement on each statement on a 5-point Likert scale ranging from “strongly agree” to “strongly disagree”. Median scores and percentage agreements were calculated. Consensus was defined a priori as being achieved if 70% or more of panel members rated a statement as “strongly agree” to “agree” after the second round. Based on feedback, 2 additional online voting rounds were conducted. Results: We received responses from 92% of Delphi panel members in round 1 and 85% in round 2. Consensus was achieved on the overall score and in all of the 5 specific key domains as essential components of the DEFASE score. Conclusions: The DEFASE score is the first comprehensive grading of food allergy severity that considers not only the severity of a single reaction, but the whole disease spectrum. An international consensus has been achieved regarding a scoring system for food allergy disease. It offers an evaluation grid, which may help to rate the severity of food allergy. Phase 3 will involve validating the scoring system in research settings, and implementing it in clinical practice.

Published
2023
Full Text
View/download PDF

3. Symptom control and health‐related quality of life in allergic rhinitis with and without comorbid asthma: A multicentre European study

Author

Subhabrata Moitra, Marzia Simoni, Sandra Baldacci, Sara Maio, Anna Angino, Patrizia Silvi, Giovanni Viegi, Stefania La Grutta, Franco Ruggiero, Gianni Bedini, Francesca Natali, Lorenzo Cecchi, Uwe Berger, Maria Prentovic, Amir Gamil, Nour Baïz, Michel Thibaudon, Samuel Monnier, Davide Caimmi, Luciana K. Tanno, Pascal Demoly, Simone Orlandini, and Isabella Annesi‐Maesano

Subjects
allergy treatment, CARAT, food allergy, pollen, RHINASTHMA, rhinitis, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Allergic rhinitis (AR) is a major non‐communicable disease that affects the health‐related quality of life (HRQoL) of patients. However, data on HRQoL and symptom control in AR patients with comorbid asthma (AR + asthma) are lacking. Methods In this multicentre, cross‐sectional study, patients with AR were screened and administered questionnaires of demographic characteristics and health conditions (symptoms/diagnosis of AR and asthma, disease severity level, and allergic conditions). HRQoL was assessed using a modified version of the RHINASTHMA questionnaire (30, ‘not at all bothered’ ‐ 150 ‘very much bothered’) and symptom control was evaluated by a modified version of the Control of Allergic Rhinitis/Asthma Test (CARAT) (0, ‘no control’ ‐ 30, ‘very high control’). Results Out of 643 patients with AR, 500 (78%) had asthma as a comorbidity, and 54% had moderate‐severe intermittent AR, followed by moderate‐severe persistent AR (34%). Compared to the patients with AR alone, patients with AR + asthma had significantly higher RHINASTHMA (e.g., median RHINASTHMA‐total score 48.5 vs. 84, respectively) and a significantly lower CARAT score (median CARAT‐total score 23 vs. 16.5, respectively). Upon stratifying asthma based on severity, AR patients with severe persistent asthma had worse HRQoL and control than those with mild persistent asthma. The association was significantly higher among non‐obese participants compared to obese ones, with RHINASTHMA‐upper symptoms score but not with CARAT. Conclusions Our observation of poorer HRQoL and symptoms control in AR patients with comorbid asthma supports the importance of a comprehensive approach for the management of AR in case of a comorbid allergic condition.

Published
2023
Full Text
View/download PDF

4. Clinical review: The suggested management pathway for urticaria in primary care

Author

Dermot Ryan, Luciana K. Tanno, Elizabeth Angier, Evangéline Clark, David Price, Torsten Zuberbier, and Marcus Maurer

Subjects
acute urticaria, chronic urticaria, primary care, urticaria management, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Urticaria is a common condition presenting both as acute and chronic disease within primary care. To those without specialist training it is poorly understood from the points of view of diagnosis and management. It causes a considerable disease burden to sufferers with marked impact on quality of life. Purpose of this review The recent publication of the EAACI/GA²LEN/EuroGuiDerm/APAAACI Guideline for the Definition, Classification, Diagnosis and Management of Urticaria guideline prompted us to take this excellent resource and re‐configure its findings and recommendations to a non‐specialist audience with particular reference to the needs of the primary care team.

Published
2022
Full Text
View/download PDF

5. Allergic manifestations of inborn errors of immunity and their impact on the diagnosis: A worldwide study

Author

Zeinab A. El-Sayed, MD, PhD, Dalia H. El-Ghoneimy, MD, PhD, José A. Ortega-Martell, MD, Nesrine Radwan, MD, PhD, Juan C. Aldave, MD, Waleed Al-Herz, MD, Maryam A. Al-Nesf, MD, ABHS, Antonio Condino-Neto, MD, PhD, Theresa Cole, MD, PhD, Brian Eley, MD, Nahla H.H. Erwa, DipRCPATH, Sara Espinosa-Padilla, PhD, Emilia Faria, MD, Nelson A. Rosario Filho, MD, PhD, Ramsay Fuleihan, MD, Nermeen Galal, MD, PhD, Elizabeth Garabedian, RN, MSLS, Mary Hintermeyer, BN, Kohsuke Imai, MD, PhD, Carla Irani, MD, MSCE, Ebtihal Kamal, MD, Nadia Kechout, MD, PhD, Adam Klocperk, MD, PhD, Michael Levin, MD, PhD, Tomas Milota, MD, PhD, Monia Ouederni, MD, Roberto Paganelli, MD, Claudio Pignata, MD, PhD, Farah N. Qamar, MBBS, FCPS, MSc, DHPE, FRCP, Isabella Quinti, MD, PhD, Sonia Qureshi, MBBS, FCPS, MSc, Nita Radhakrishnan, MD, PhD, Nima Rezaei, MD, PhD, John Routes, MD, PhD, Surjit Singh, MD, DCH (Lon.), FRCP (Lon.), FRCPCH (Lon.), FAMS, Sangeetha Siniah, MBBS, MRCPCH, Intisar Abdel-Hakam Taha, MD, SMSB, Luciana K. Tanno, MD, Ph.D, Ben Van Dort, BN, Alla Volokha, MD, PhD, DSc, and Kathleen Sullivan, MD, PhD

Subjects
Primary immunodeficiency, Asthma, Atopic dermatitis, IVIG, Omalizumab, Anaphylaxis, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Allergies have long been observed in Inborn Errors of Immunity (IEI) and might even be the first presentation resulting in delayed diagnosis or misdiagnosis in some cases. However, data on the prevalence of allergic diseases among IEI patients are limited and contradictory. Objective: To provide a worldwide view of allergic diseases, across a broad spectrum of IEI, and their impact on the timely diagnosis of IEI. Methods: This is a worldwide study, conceived by the World Allergy Organization (WAO) Inborn Errors of Immunity Committee. A questionnaire was developed and pilot-tested and was sent via email to collect data from 61 immunology centers known to treat pediatric and/or adult IEI patients in 41 countries. In addition, a query was submitted to The United States Immunodeficiency Network (USIDNET) at its website. Results: Thirty centers in 23 countries caring for a total of 8450 IEI patients responded. The USIDNET dataset included 2332 patients. Data from responders showed that a median (IQR) of 16.3% (10–28.8%) of patients experienced allergic diseases during the course of their IEI as follows: 3.6% (1.3–11.3%) had bronchial asthma, 3.6% (1.9–9.1%) atopic dermatitis, 3.0% (1.0–7.8%) allergic rhinitis, and 1.3% (0.5–3.3%) food allergy. As per the USIDNET data, the frequency of allergy among IEI patients was 68.8% (bronchial asthma in 46.9%). The percentage of IEI patients who presented initially with allergic disorders was 8% (5–25%) and diagnosis delay was reported in 7.5% (0.9–20.6%). Predominantly antibody deficiencies had the highest frequency of allergic disease followed by combined immunodeficiency with a frequency of 40.3% (19.2–62.5%) and 20.0% (10–32%) respectively. As per the data of centers, anaphylaxis occurred in 25/8450 patients (0.3%) whereas per USIDNET dataset, it occurred in 249/2332 (10.6%); drugs and food allergy were the main causes in both datasets. Conclusions: This multinational study brings to focus the relation between allergic diseases and IEI. Major allergies do occur in IEI patients but were less frequent than the general population. Initial presentation with allergy could adversely affect the timely diagnosis of IEI. There is a need for policies to raise awareness and educate primary care and other referring specialties on the association of allergic diseases with IEI. This study provides a network among centers for future prospective studies in the field.

Published
2022
Full Text
View/download PDF

6. WAO-ARIA consensus on chronic cough – Part III: Management strategies in primary and cough-specialty care. Updates in COVID-19

Author

Philip W. Rouadi, MD, Samar A. Idriss, MD, Jean Bousquet, MD, PhD, Tanya M. Laidlaw, MD, Cecilio R. Azar, MD, Mona S. Al-Ahmad, MD, FRCPCP, Anahi Yañez, MD, Maryam Ali Y. Al-Nesf, MD, MSc R, CABHS, Talal M. Nsouli, MD, FACAAI, FAAAAI, Sami L. Bahna, MD, DrPH, Eliane Abou-Jaoude, MD, Fares H. Zaitoun, MD, FACAAI, Usamah M. Hadi, MD, FACS, ERS, PARS, Peter W. Hellings, MD, PhD, Glenis K. Scadding, MD, FRCP, Peter K. Smith, BMedSci, MBBS, FRACP, PhD, Mario Morais-Almeida, MD, René Maximiliano Gómez, MD, PhD, Sandra N. Gonzalez Diaz, MD, PhD, Ludger Klimek, MD, PhD, Georges S. Juvelekian, MD, FCCP, D’ABSM, Moussa A. Riachy, MD, FCCP, Giorgio Walter Canonica, MD, David Peden, MD, Gary W.K. Wong, MD, James Sublett, MD, Jonathan A. Bernstein, MD, Lianglu Wang, MD, Luciana K. Tanno, MD, PhD, Manana Chikhladze, PhD, Michael Levin, MD, Yoon-Seok Chang, MD, PhD, Bryan L. Martin, DO, Luis Caraballo, MD, PhD, Adnan Custovic, MD, PhD, Jose Antonio Ortego-Martell, MD, Olivia J.Ly Lesslar, MBBS BIR, Erika Jensen-Jarolim, MD, Motohiro Ebisawa, MD, Alessandro Fiocchi, MD, and Ignacio J. Ansotegui, MD, PhD

Subjects
Upper airway cough syndrome, Lower airway disease, Reflux cough, Chronic cough management, Neuromodulators, Speech therapy, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Chronic cough management necessitates a clear integrated care pathway approach. Primary care physicians initially encounter the majority of chronic cough patients, yet their role in proper management can prove challenging due to limited access to advanced diagnostic testing. A multidisciplinary approach involving otolaryngologists and chest physicians, allergists, and gastroenterologists, among others, is central to the optimal diagnosis and treatment of conditions which underly or worsen cough. These include infectious and inflammatory, upper and lower airway pathologies, or gastro-esophageal reflux. Despite the wide armamentarium of ancillary testing conducted in cough multidisciplinary care, such management can improve cough but seldom resolves it completely. This can be due partly to the limited data on the role of tests (eg, spirometry, exhaled nitric oxide), as well as classical pharmacotherapy conducted in multidisciplinary specialties for chronic cough. Other important factors include presence of multiple concomitant cough trigger mechanisms and the central neuronal complexity of chronic cough. Subsequent management conducted by cough specialists aims at control of cough refractory to prior interventions and includes cough-specific behavioral counseling and pharmacotherapy with neuromodulators, among others. Preliminary data on the role of neuromodulators in a proof-of-concept manner are encouraging but lack strong evidence on efficacy and safety. Objectives: The World Allergy Organization (WAO)/Allergic Rhinitis and its Impact on Asthma (ARIA) Joint Committee on Chronic Cough reviewed the recent literature on management of chronic cough in primary, multidisciplinary, and cough-specialty care. Knowledge gaps in diagnostic testing, classical and neuromodulator pharmacotherapy, in addition to behavioral therapy of chronic cough were also analyzed. Outcomes: This third part of the WAO/ARIA consensus on chronic cough suggests a management algorithm of chronic cough in an integrated care pathway approach. Insights into the inherent limitations of multidisciplinary cough diagnostic testing, efficacy and safety of currently available antitussive pharmacotherapy, or the recently recognized behavioral therapy, can significantly improve the standards of care in patients with chronic cough.

Published
2022
Full Text
View/download PDF

7. WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation — Updates in COVID-19

Author

Philip W. Rouadi, MD, Samar A. Idriss, MD, Jean Bousquet, MD, PhD, Tanya M. Laidlaw, MD, Cecilio R. Azar, MD, Mona S. Al-Ahmad, MD, FRCPCP, Anahi Yañez, MD, Maryam Ali Y. Al-Nesf, MD, MSc R, CABHS, Talal M. Nsouli, MD, FACAAI, FAAAAI, Sami L. Bahna, MD, DrPH, Eliane Abou-Jaoude, MD, Fares H. Zaitoun, MD, FACAAI, Usamah M. Hadi, MD, FACS, ERS, PARS, Peter W. Hellings, MD, PhD, Glenis K. Scadding, MD, FRCP, Peter K. Smith, BMedSci, MBBS, FRACP, PhD, Mario Morais-Almeida, MD, René Maximiliano Gómez, MD, PhD, Sandra N. Gonzalez Diaz, MD, PhD, Ludger Klimek, MD, PhD, Georges S. Juvelekian, MD, FCCP, D'ABSM, Moussa A. Riachy, MD, FCCP, Giorgio Walter Canonica, MD, David Peden, MD, Gary W.K. Wong, MD, James Sublett, MD, Jonathan A. Bernstein, MD, Lianglu Wang, MD, Luciana K. Tanno, MD, PhD, Manana Chikhladze, PhD, Michael Levin, MD, Yoon-Seok Chang, MD, PhD, Bryan L. Martin, DO, Luis Caraballo, MD, PhD, Adnan Custovic, MD, PhD, Jose Antonio Ortega-Martell, MD, Erika Jensen-Jarolim, MD, Motohiro Ebisawa, MD, Alessandro Fiocchi, MD, and Ignacio J. Ansotegui, MD, PhD

Subjects
Multifactorial cough, Cough phenotypes, Type 2 inflammation, COVID 19, Reflux-cough, Upper airway cough syndrome, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Chronic cough can be triggered by respiratory and non-respiratory tract illnesses originating mainly from the upper and lower airways, and the GI tract (ie, reflux). Recent findings suggest it can also be a prominent feature in obstructive sleep apnea (OSA), laryngeal hyperresponsiveness, and COVID-19. The classification of chronic cough is constantly updated but lacks clear definition. Epidemiological data on the prevalence of chronic cough are informative but highly variable. The underlying mechanism of chronic cough is a neurogenic inflammation of the cough reflex which becomes hypersensitive, thus the term hypersensitive cough reflex (HCR). A current challenge is to decipher how various infectious and inflammatory airway diseases and esophageal reflux, among others, modulate HCR. Objectives: The World Allergy Organization/Allergic Rhinitis and its Impact on Asthma (WAO/ARIA) Joint Committee on Chronic Cough reviewed the current literature on classification, epidemiology, presenting features, and mechanistic pathways of chronic cough in airway- and reflux-related cough phenotypes, OSA, and COVID-19. The interplay of cough reflex sensitivity with other pathogenic mechanisms inherent to airway and reflux-related inflammatory conditions was also analyzed. Outcomes: Currently, it is difficult to clearly ascertain true prevalence rates in epidemiological studies of chronic cough phenotypes. This is likely due to lack of standardized objective measures needed for cough classification and frequent coexistence of multi-organ cough origins. Notwithstanding, we emphasize the important role of HCR as a mechanistic trigger in airway- and reflux-related cough phenotypes. Other concomitant mechanisms can also modulate HCR, including type2/Th1/Th2 inflammation, presence or absence of deep inspiration-bronchoprotective reflex (lower airways), tissue remodeling, and likely cough plasticity, among others.

Published
2021
Full Text
View/download PDF

8. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee

Author

Paul J. Turner, Ignacio J. Ansotegui, Dianne E. Campbell, Victoria Cardona, Motohiro Ebisawa, Yehia El-Gamal, Stanley Fineman, Mario Geller, Alexei Gonzalez-Estrada, Paul A. Greenberger, Agnes S.Y. Leung, Michael E. Levin, Antonella Muraro, Mario Sánchez Borges, Gianenrico Senna, Luciana K. Tanno, Bernard Yu-Hor Thong, and Margitta Worm

Subjects
Adverse event following immunization, Anaphylaxis, COVID-19, Polyethylene glycol, Vaccine, Immunologic diseases. Allergy, RC581-607
Abstract

Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine.In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.

Published
2021
Full Text
View/download PDF

9. Management of anaphylaxis in Latin America: current situation

Author

Victoria Cardona, Alberto Álvarez-Perea, Ignacio J. Ansotegui, Alfredo Arias-Cruz, Sandra Nora González-Díaz, Patricia Latour-Staffeld, Juan Carlos Ivancevich, Mario Sánchez-Borges, Carlos D Serrano, Dirceu Solé, and Luciana K. Tanno

Subjects
Anafilaxia, Adrenalina, Guía de práctica clínica, América Latina, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Anaphylaxis is a systemic and severe allergic reaction, which can be fatal. The first-line treatment of choice, according to international guidelines, is intramuscular adrenaline. However, different studies show that the performance of health professionals managing anaphylaxis is often inadequate Objective: To assess the current resources available in Latin American countries for the diagnosis and treatment of anaphylaxis. Methods: Online survey promoted by the Latin American Society of Allergy and Immunology to representatives of the national allergy societies of Latin American countries. Results: Responses were received from 10 countries out of the 14 countries invited to participate. Only five of the countries have clinical practice guidelines in anaphylaxis. Adrenaline autoinjectors are available only in two countries, Argentina and Brazil, but are not subsidized by public health systems. In all countries, adrenaline is available in ampoules, which is the presentation usually prescribed to patients for self-administration. The use of adrenaline was estimated to be less than 50 % of cases in five countries, while antihistamines and corticosteroids are almost always used. The determination of serum tryptase is possible in some health centers, often private, in five of the countries surveyed. Conclusion: It is necessary to improve resources related to the diagnosis and management of anaphylaxis in Latin American countries.

Published
2017
Full Text
View/download PDF

10. International survey on skin patch test procedures, attitudes and interpretation

Author

Luciana K. Tanno, Razvigor Darlenski, Silvia Sánchez-Garcia, Matteo Bonini, Andrea Vereda, Pavel Kolkhir, Dario Antolin-Amerigo, Vesselin Dimov, Claudia Gallego-Corella, Juan Carlos Aldave Becerra, Alexander Diaz, Virginia Bellido Linares, Leonor Villa, Lanny J. Rosenwasser, Mario Sanchez-Borges, Ignacio Ansotegui, Ruby Pawankar, and Thomas Bieber

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Background Skin patch test is the gold standard method in diagnosing contact allergy. Although used for more than 100 years, the patch test procedure is performed with variability around the world. A number of factors can influence the test results, namely the quality of reagents used, the timing of the application, the patch test series (allergens/haptens) that have been used for testing, the appropriate interpretation of the skin reactions or the evaluation of the patient’s benefit.Methods We performed an Internet –based survey with 38 questions covering the educational background of respondents, patch test methods and interpretation. The questionnaire was distributed among all representatives of national member societies of the World Allergy Organization (WAO), and the WAO Junior Members Group.Results One hundred sixty-nine completed surveys were received from 47 countries. The majority of participants had more than 5 years of clinical practice (61 %) and routinely carried out patch tests (70 %). Both allergists and dermatologists were responsible for carrying out the patch tests. We could observe the use of many different guidelines regardless the geographical distribution. The use of home-made preparations was indicated by 47 % of participants and 73 % of the respondents performed 2 or 3 readings. Most of the responders indicated having patients with adverse reactions, including erythroderma (12 %); however, only 30 % of members completed a consent form before conducting the patch test.Discussion The heterogeneity of patch test practices may be influenced by the level of awareness of clinical guidelines, different training backgrounds, accessibility to various types of devices, the patch test series (allergens/haptens) used for testing, type of clinical practice (public or private practice, clinical or research-based institution), infrastructure availability, financial/commercial implications and regulations among others.Conclusion There is a lack of a worldwide homogeneity of patch test procedures, and this raises concerns about the need for standardization and harmonization of this important diagnostic procedure. Keywords: Allergy, Contact dermatitis, Sensitization, Skin patch test, Survey

Published
2016
Full Text
View/download PDF

11. Economic burden of drug-induced anaphylaxis: what can we do better?

Author

Barbara, Cardoso, Teresa, Moscoso, Mário, Morais-Almeida, Pascal, Demoly, Luciana K, Tanno, Hospital CUF Descobertas, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), World Health Organisation (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Médecine de précision par intégration de données et inférence causale (PREMEDICAL), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Desbrest de santé publique (IDESP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
MESH: Drug Hypersensitivity, MESH: Humans, MESH: Anaphylaxis / epidemiology, Immunology, MESH: Health Care Costs, Financial Stress, Health Care Costs, MESH: Cost of Illness, MESH: Absenteeism, Drug Hypersensitivity, MESH: Anaphylaxis / prevention & control, Cost of Illness, Absenteeism, Humans, Immunology and Allergy, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Anaphylaxis / diagnosis, MESH: Financial Stress, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Anaphylaxis
Abstract

International audience; Purpose of review: This systematic review evaluates published data related to the economic burden of drug-induced anaphylaxis (DIA) to understand preventive cost saving measures that could reduce the burden of these conditions.Recent findings: Although DIA has a relevant societal impact, there are limited and heterogenous available data related to its cost. Direct costs related to the management of acute phase of DIA was estimated by $529.6 to $3 125, depending on the number of emergency room visits/hospitalizations, emergency kits and transports in ambulance. Direct costs of investigations of DIA varied from $288 to $2 292.95 and the desensitization was estimated by $6 796. Main variables for this were: personnel, allergy screening procedures, medical consumables and space cost. The mean indirect cost was based on a mean absenteeism of 3 days per DIA corresponding to $381.2.Summary: More than reviewing the published data, we were able to identify variables that, if correctly managed, can reduce the economic burden of DIA, such as adjusting the timing of referral and etiological diagnosis, identification of potential risk and/or co-factors, correct written recommendations to patients. The evidence presented highlights the need of optimization of healthcare patients to patients suffering from DIA.

Published
2022

12. Editorial: Drug allergy

Author

Luciana K. Tanno and Paul Whitaker

Subjects
Drug Hypersensitivity, Immunology, Immunology and Allergy, Humans
Published
2022

13. Symptom control and health-related quality of life in allergic rhinitis with and without comorbid asthma: a multicentre European study

Author

Subhabrata Moitra, Marzia Simoni, Sandra Baldacci, Sara Maio, Anna Angino, Patrizia Silvi, Giovanni Viegi, Stefania La Grutta, Franco Ruggiero, Gianni Bedini, Francesca Natali, Lorenzo Cecchi, Uwe Berger, Maria Prentovic, Amir Gamil, Nour Baïz, Michel Thibaudon, Samuel Monnier, Davide Caimmi, Luciana K. Tanno, Pascal Demoly, Simone Orlandini, and Isabella Annesi‐Maesano

Subjects
Pulmonary and Respiratory Medicine, Immunology, Immunology and Allergy
Abstract

Background: Allergic rhinitis (AR) is a major non-communicable disease that affects the health-related quality of life (HRQoL) of patients. AR is significantly related to asthma also affecting HRQoL. However, data on HRQoL and symptom control in AR patients with comorbid asthma are lacking. Objective: To assess the differences of symptom control and HRQoL in AR patients with and without comorbid asthma. Methods: In this multicentre, cross-sectional study, patients with AR were screened and administered questionnaires of demographic characteristics and health conditions (symptoms/diagnosis of AR and asthma, disease severity level, and allergic conditions). HRQoL was assessed using a modified version of the RHINASTHMA questionnaire and symptom control was evaluated by a modified version of the Control of Allergic Rhinitis/Asthma Test (CARAT). Results: Out of 643 patients with AR, 500 (78%) had asthma as a comorbidity, and 54% had moderate-severe intermittent AR, followed by moderate-severe persistent AR (34%). Patients with both AR and asthma had significantly higher RHINASTHMA scores than the patients with AR alone (e.g., median RHINASTHMA-total score 84 vs. 48.5, respectively). Conversely, CARAT scores were significantly lower in AR with comorbid asthma than in the patients with AR alone (median CARAT-total score 16.5 vs. 23, respectively). Upon stratifying asthma based on severity, AR patients with severe persistent asthma had worse HRQoL and control than AR patients with mild persistent asthma. Conclusions: Our observation of poorer HRQoL and symptoms control in AR patients with comorbid asthma supports the importance of a comprehensive approach for the management of AR in case of a comorbid allergic condition.

Published
2022

14. Global patterns of drug allergy-induced fatalities: a wake-up call to prevent avoidable deaths

Author

Luciana K, Tanno, Amélie, Gauthier, Salome, Allichon, Pascal, Demoly, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), World Health Organisation (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Université Laval [Quebec] (CHUL), CHU de Québec–Université Laval, Université Laval [Québec] (ULaval)-Université Laval [Québec] (ULaval), Médecine de précision par intégration de données et inférence causale (PREMEDICAL), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut Desbrest de santé publique (IDESP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
Drug Hypersensitivity, Epinephrine, Immunology, MESH: Contrast Media / adverse effects, Humans, Contrast Media, Immunology and Allergy, [SDV.IMM]Life Sciences [q-bio]/Immunology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Anaphylaxis, Asthma, MESH: Anaphylaxis / chemically induced, Anaphylaxis / epidemiology, Anaphylaxis / prevention & control Anti-Bacterial, Agents / adverse effects, Anti-Bacterial Agents
Abstract

International audience; Purpose of review: To identify patterns and key issues though a systematic review in order to support prevention strategies and reduce avoidable deaths related to drug-induced anaphylaxis (DAF).Recent findings: DAF rate has been estimated by 0.13-0.53/106 population/year. General global trends of DAF are increasing over time, mostly occurring at healthcare settings (62%) with a similar gender distribution and an average age of 53 years. Antibiotics, anaesthetics, radio-contrast media and NSAIDs were the most frequently implicated agents. Main comorbidities were personal history of drug allergy, cardiovascular diseases and asthma. Main manifestations were cardiovascular and respiratory commitments. Use of adrenaline is mentioned in only 29% of the articles.Summary: DAF is increasing worldwide and most cases are iatrogenic. This first systematic review of DAF identified key gaps and served as a wake-up call to prevent avoidable deaths. Phenotype at risk for DAF was represented by patients aged more than 54 years, with personal history of drug allergy/hypersensitivity with no or incomplete allergological work-up, cardiovascular disease and/or asthma with need of hospitalization and/or frequent healthcare assistance. Additional risk for those who need frequent use of intravenous antibiotics and/or undergoing surgery or image investigation with radiocontrast media.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results